Kitty Yale joined Akero in October 2018 as Chief Development Officer. In her current role, she leads the clinical development of Efruxifermin (fc-FGF21 analog) in NASH
Kitty has over twenty-five years of drug development experience in the biotechnology and pharmaceutical industries. Prior to joining Akero, she spent 17 years at Gilead, where she led global clinical operations and management of the company’s oncology, HIV, inflammation, and liver disease trials. As VP of Clinical Operations at Gilead, Kitty led global development programs resulting in eight drug approvals in the US, EMEA, Canada, Korea, Japan, and China. She holds a BSc in Applied Biology from Glasgow Caledonian University.
Kitty lives in San Francisco with her husband Kevin and their 2 teenage daughters. She enjoys spending time together with her family and friends, hiking, skiing and cooking.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.